Pharmala Biotech Holdings (XCNQ:MDMA) ROCE % : -62.55% (As of Feb. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharmala Biotech Holdings's annualized ROCE % for the quarter that ended in Feb. 2024 was -62.55%.

Pharmala Biotech Holdings ROCE % Historical Data

The historical data trend for Pharmala Biotech Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings ROCE % Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

ROCE %

-94.47

-43.23

-46.38

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial							-52.82	-87.43	25.04	56.97	-62.55

Pharmala Biotech Holdings ROCE % Calculation

Pharmala Biotech Holdings's annualized ROCE % for the fiscal year that ended in Aug. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	-0.763	/	( ( (2.33 - 0.424)	+	(2.413 - 1.029) )	/ 2 )
	=	-0.763	/	( (1.906	+	1.384)	/ 2 )
	=	-0.763	/	1.645
	=	-46.38 %

Pharmala Biotech Holdings's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-0.892	/	( ( (2.387 - 0.878)	+	(2.481 - 1.138) )	/ 2 )
	=	-0.892	/	( ( 1.509	+	1.343 )	/ 2 )
	=	-0.892	/	1.426
	=	-62.55 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

Pharmala Biotech Holdings (XCNQ:MDMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharmala Biotech Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PMBHF:USA

Address

82 Richmond Street East, Toranto, ON, CAN, M5C 1P1

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines